Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $7.00M | $12.1M |
| Revenue growth | — | — | — | — | — | — | 73.4% |
| Operating income | -$28.1M | -$58.8M | -$114M | -$124M | -$132M | -$140M | -$105M |
| Operating margin | — | — | — | — | — | -1995.9% | -861.3% |
| Net income | -$27.6M | -$56.9M | -$112M | -$115M | -$122M | -$127M | -$99.5M |
| Net margin | — | — | — | — | — | -1816.8% | -819.6% |
| EPS (diluted) | -$16.52 | -$4.56 | -$2.43 | -$2.44 | -$2.02 | -$1.68 | -$1.29 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.7M | -$46.2M | -$83.5M | -$83.7M | -$107M | -$103M | -$56.3M |
| Capital expenditures | $780K | $621K | $2.32M | $3.02M | $3.51M | $764K | $67.0K |
| Free cash flow | -$26.4M | -$46.8M | -$85.9M | -$86.7M | -$111M | -$104M | -$56.4M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.9M | $218M | $31.8M | $30.6M | $25.3M | $12.5M | $35.3M |
| Total assets | $21.9M | $224M | $305M | $221M | $278M | $176M | $141M |
| Total liabilities | $4.84M | $11.4M | $19.2M | $25.1M | $40.6M | $44.1M | $72.7M |
| Shareholders' equity | -$49.4M | $212M | $286M | $195M | $237M | $131M | $68.6M |
| Retained earnings | -$50.5M | -$107M | -$219M | -$335M | -$456M | -$584M | -$683M |
| Shares (wtd avg diluted) | — | — | 46.0M | 47.4M | 60.4M | 75.8M | 77.0M |
Every figure is extracted from Prelude Therapeutics Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.